Copyright 2009 Medical News Today Latest Dermatology News From Medical News Today. http://www.medicalnewstoday.com/sections/dermatology/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Sat, 07 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170191.php http://www.medicalnewstoday.com/articles/170191.php Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). Dermatology Fri, 06 Nov 2009 10:00:00 PST http://www.medicalnewstoday.com/articles/170134.php http://www.medicalnewstoday.com/articles/170134.php Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Dermatology Wed, 04 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/169744.php http://www.medicalnewstoday.com/articles/169744.php Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc. Dermatology Wed, 04 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/169696.php http://www.medicalnewstoday.com/articles/169696.php As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology. Lupus Tue, 03 Nov 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/169666.php http://www.medicalnewstoday.com/articles/169666.php Researchers at Rush University Medical Center and Argonne National Laboratory are collaborating on a study to determine if an imaging technique used by NASA to inspect the space shuttle can be used to predict tissue damage often experienced by breast cancer patients undergoing radiation therapy. The study is examining the utility of three-dimensional thermal tomography in radiation oncology. Breast Cancer Mon, 02 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169490.php http://www.medicalnewstoday.com/articles/169490.php Greyson International, Inc. (GYSN.PK) announced that it has received results from a third-party clinical study conducted on Trilexon®, a new delivery system designed by Greyson that improves the effectiveness of topical applications. Dermatology Sat, 31 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/169348.php http://www.medicalnewstoday.com/articles/169348.php At its most benign, the autoimmune disease scleroderma can discolor parts of the skin of its sufferers. At its most pernicious, it can thicken and harden their skin, their blood vessels, and their internal organs before, in many cases, killing them. In all its forms, scleroderma gives Dartmouth geneticist Michael Whitfield, his graduate students, and his postdoctoral researchers a sense of urgency in their search for the triggers of the chronic condition. Dermatology Sat, 31 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/169380.php http://www.medicalnewstoday.com/articles/169380.php NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia. "This model tests both the penetration of the nail as well as the effectiveness of the compounds against the targeted fungus. Infectious Diseases / Bacteria / Viruses Fri, 30 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/169235.php http://www.medicalnewstoday.com/articles/169235.php The comparative study of chronic wound treatment at the Hospital Civil of Cd. Victoria, Tamaulipas, Mexico, was concluded successfully. Due to the significantly superior therapeutic success the Ministry of Health ordered the control to be abandoned and moved to Hemospray treatment for ethical reasons. 22 of the 24 patients within the Hemospray group were healed completely, while 22 of the 24 patients of the control group showed no comparable progress. Dermatology Thu, 29 Oct 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/169078.php http://www.medicalnewstoday.com/articles/169078.php Findings from a national survey Psoriasis Uncovered, show that for those with the most severe1 form of the condition, psoriasis has an irreversible effect on one in two patients' lives. Eczema / Psoriasis Wed, 28 Oct 2009 20:00:00 PST http://www.medicalnewstoday.com/articles/169029.php http://www.medicalnewstoday.com/articles/169029.php PhotoMedex, Inc. (Nasdaq: PHMD) a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009. Eczema / Psoriasis Wed, 28 Oct 2009 11:00:00 PST http://www.medicalnewstoday.com/articles/169072.php http://www.medicalnewstoday.com/articles/169072.php A US group that arranged for an independent lab to test 10 children's face paints for heavy metals and also review ingredient labels of Halloween products sold at a seasonal holiday store, has reported that Halloween face paints are contaminated with lead and other heavy metals, and other Halloween products contain hazardous ingredients. They recommend that parents consider safer alternatives for their children. Pediatrics / Children's Health Wed, 28 Oct 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/168980.php http://www.medicalnewstoday.com/articles/168980.php Face and Hand Transplants - Ready to Become Mainstream Medicine? Though once inconceivable, face and hand transplants are quickly making themselves more present, both in the operating room and in the media. The world's first hand transplant was performed more than a decade ago, and the first partial-face transplant performed in the United States (and most extensive procedure to date) was completed this year. Cosmetic Medicine / Plastic Surgery Tue, 27 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168728.php http://www.medicalnewstoday.com/articles/168728.php Anal itching, also known as itchy bottom, pruritus ani or anusitis, is irritation and sometimes inflammation of the anus - located at the exit of the rectum. Itching severity varies and is usually exacerbated by such factors as type of clothing worn, whether the patient is seated or upright, moisture levels, pressure and general rubbing of the anal area. Dermatology Sun, 25 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168558.php http://www.medicalnewstoday.com/articles/168558.php The European Medicines Agency has been formally notified by Arpida A/S of its decision to withdraw its application for a centralised marketing authorisation for the medicine Mersarex (iclaprim), 12.8 mg/ml concentrate for solution for infusion. Mersarex was expected to be used for the treatment of complicated skin and soft tissue infections. The application for the marketing authorisation for Mersarex was submitted to the Agency on 25 July 2008. Dermatology Sat, 24 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/168527.php http://www.medicalnewstoday.com/articles/168527.php Spend a little time people-watching at the beach and you're bound to notice differences in the amount, thickness and color of people's body hair. Then head to the zoo and compare people to chimps, our closest living relatives. The body hair difference is even more pronounced between the two species than within our own species. Dermatology Sat, 24 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/168573.php http://www.medicalnewstoday.com/articles/168573.php The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew Plc (LSE: SN; NYSE: SNN), highlighted the results of a multi-center study which demonstrates that gauze-based Negative Pressure Wound Therapy (NPWT) achieves many of the common treatment goals defined for foam-based NPWT systems. These goals include a reduction in wound dimension, exudate, and improvement in granulation tissue. Dermatology Fri, 23 Oct 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/168439.php http://www.medicalnewstoday.com/articles/168439.php Using a new modelling strategy, researchers in Japan have designed a new enzyme that shows significant promise compared with current therapeutic proteins used to treat patients with Fabry disease, a rare genetic disorder that affects about 1 in 40,000 people and often results in cardiac and renal failure. Genetics Fri, 23 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/168384.php http://www.medicalnewstoday.com/articles/168384.php Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy also known as phototherapy. Eczema / Psoriasis Thu, 22 Oct 2009 18:00:00 PST http://www.medicalnewstoday.com/articles/168360.php http://www.medicalnewstoday.com/articles/168360.php PPD, Inc. (NASDAQ:PPDI) announced Sandra Luikenhuis, Ph.D., executive director of PPD® Dermatology, will present at the 2009 Boston Biotech R&D Conference in Boston, Mass., where she will introduce PPD Dermatology and discuss how the team is developing novel, science-based dermatologic therapies using a unique portfolio of in vitro assay systems and highly specialized expertise. Dr. Luikenhuis's presentation is Oct. 27 at 11 a.m. ET at the Harvard Medical School. Dermatology Thu, 22 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168205.php http://www.medicalnewstoday.com/articles/168205.php Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced that MediWound Ltd., a company in which Teva holds an 11% interest, reported positive results from a pre planned interim analysis of a phase III trial for Debrase®, an enzymatic debriding agent for burns. Dermatology Wed, 21 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168030.php http://www.medicalnewstoday.com/articles/168030.php Microdermabrasion using a coarse diamond-studded instrument appears to induce molecular changes in the skin of older adults that mimic the way skin is remodeled during the wound healing process, according to a report in the October issue of Archives of Dermatology, one of the JAMA/Archives journals. "Microdermabrasion is a popular procedure for skin rejuvenation," the authors write as background information in the article. Dermatology Wed, 21 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168031.php http://www.medicalnewstoday.com/articles/168031.php Many resident physicians are not trained in skin cancer examinations, nor have they ever observed or practiced the procedure, according to a report in the October issue of Archives of Dermatology, one of the JAMA/Archives journals. Melanoma is the only cancer that can be detected early for which U.S. death rates are not decreasing, according to background information in the article. Melanoma / Skin Cancer Mon, 19 Oct 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/167792.php http://www.medicalnewstoday.com/articles/167792.php The National Institutes of Health has announced that it is awarding 15 new grants to further develop and test the Patient Reported Outcomes Measurement Information System (PROMIS). Managed by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), PROMIS aims to revolutionize the way patient reported outcome tools are selected and employed in clinical research and practice. IT / Internet / E-mail Mon, 19 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/167782.php http://www.medicalnewstoday.com/articles/167782.php Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news was presented at the annual meeting of the American College of Rheumatology on October 18 in Philadelphia. "There has never been a drug that has been shown to be effective for this condition. Cancer / Oncology